168 related articles for article (PubMed ID: 12455303)
1. Exemestane: treatment of breast cancer with selective inactivation of aromatase.
Higa GM
Am J Health Syst Pharm; 2002 Nov; 59(22):2194-2201; quiz 2202-4. PubMed ID: 12455303
[TBL] [Abstract][Full Text] [Related]
2. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Clemett D; Lamb HM
Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
[TBL] [Abstract][Full Text] [Related]
3. Exemestane: a review of its use in postmenopausal women with breast cancer.
Deeks ED; Scott LJ
Drugs; 2009; 69(7):889-918. PubMed ID: 19441873
[TBL] [Abstract][Full Text] [Related]
4. Exemestane: a novel aromatase inactivator for breast cancer.
Jones SA; Jones SE
Clin Breast Cancer; 2000 Oct; 1(3):211-6. PubMed ID: 11899645
[TBL] [Abstract][Full Text] [Related]
5. Exemestane in postmenopausal women with early or advanced breast cancer: a review.
Bertelli G; Gangadhara S
Expert Opin Pharmacother; 2010 Aug; 11(11):1933-42. PubMed ID: 20569090
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology and clinical experience with exemestane.
Lønning PE
Expert Opin Investig Drugs; 2000 Aug; 9(8):1897-905. PubMed ID: 11060785
[TBL] [Abstract][Full Text] [Related]
7. Drug safety evaluation of exemestane.
Lintermans A; Neven P; Paridaens R
Expert Opin Drug Saf; 2011 May; 10(3):473-87. PubMed ID: 21428848
[TBL] [Abstract][Full Text] [Related]
8. The role of aromatase inactivators in the treatment of breast cancer.
Lønning PE
Int J Clin Oncol; 2002 Aug; 7(4):265-70. PubMed ID: 12202980
[TBL] [Abstract][Full Text] [Related]
9. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.
Jones S; Vogel C; Arkhipov A; Fehrenbacher L; Eisenberg P; Cooper B; Honig S; Polli A; Whaley F; di Salle E; Tiffany J; Consonni A; Miller L
J Clin Oncol; 1999 Nov; 17(11):3418-25. PubMed ID: 10550136
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacological and clinical profile of exemestane (Aromasin), a novel irreversible aromatase inhibitor].
Tahara M; Nomura S; Hashimoto M
Nihon Yakurigaku Zasshi; 2003 Oct; 122(4):345-54. PubMed ID: 14501171
[TBL] [Abstract][Full Text] [Related]
11. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.
Dixon JM
Expert Rev Anticancer Ther; 2002 Jun; 2(3):267-75. PubMed ID: 12113050
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
13. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review).
Crucitta E; Fornier MN; Locopo N; Silvestris N; Lorusso V; De Lena M
Int J Oncol; 2002 Jun; 20(6):1283-8. PubMed ID: 12012011
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
Goss PE; Strasser K
Drugs; 2002; 62(6):957-66. PubMed ID: 11929341
[TBL] [Abstract][Full Text] [Related]
15. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
Michaud LB; Buzdar AU
Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021
[TBL] [Abstract][Full Text] [Related]
16. Unravelling exemestane: From biology to clinical prospects.
Sobral AF; Amaral C; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2016 Oct; 163():1-11. PubMed ID: 26992705
[TBL] [Abstract][Full Text] [Related]
17. Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
Prescrire Int; 2001 Aug; 10(54):108-9. PubMed ID: 11718178
[TBL] [Abstract][Full Text] [Related]
18. Exemestane.
Scott LJ; Wiseman LR
Drugs; 1999 Oct; 58(4):675-80; discussion 681-2. PubMed ID: 10551437
[TBL] [Abstract][Full Text] [Related]
19. Are differences in the available aromatase inhibitors and inactivators significant?
Johnson PE; Buzdar A
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4360s-4368s; discussion 4411s-4412s. PubMed ID: 11916226
[TBL] [Abstract][Full Text] [Related]
20. Exemestane experience in breast cancer treatment.
Lønning PE; Paridaens R; Thürlimann B; Piscitelli G; di Salle E
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):151-5. PubMed ID: 9365185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
